BACKGROUND: Laboratory testing and treatments for chronic lymphocytic leukemia (CLL) have changed dramatically within the last decade. The authors evaluated changes in patterns of real-world testing and treatment over time by comparing 2 population-based cohorts. METHODS: The National Cancer Institute-sponsored Patterns of Care study was conducted among patients with CLL who were sampled from 14 Surveillance, Epidemiology, and End Results (SEER) program registries. Demographics, testing, and treatment data were abstracted from medical records within 24 months of diagnosis. RESULTS: A total of 1008 patients diagnosed in 2008 and 1367 patients diagnosed in 2014 were included. There was a significant increase in fluorescence in situ hybridization (FISH) testing, immunoglobulin heavy-chain variable region gene (IgV H ) mutation analyses, and lymph node biopsies between 2008 and 2014. FISH testing was performed in the majority of, but not all, treated patients (53% in 2008, which increased to 62% in 2014). Some differences in the receipt of FISH testing by age and insurance status were observed over time (older patients and Medicare patients without private insurance were less likely to be tested in 2014). There were contrasting testing patterns noted by practice type and year, with nonteaching hospitals more likely to perform bone marrow biopsies in 2008, and teaching hospitals more likely to perform FISH and IgV H testing in 2014. There also were differences in treatments over time, with the use of bendamustine and rituximab being more common in 2014, at the expense of fludarabine, cyclophosphamide, and rituximab. CONCLUSIONS: There have been rapidly changing practices in the testing and treatment patterns of patients with CLL within the last decade. Cancer 2019;125:135-143.
INTRODUCTION
The management of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has undergone substantial changes with regard to the use of both prognostic laboratory testing and standard-of-care therapy within the last decade. Prognostic testing has included immunoglobulin heavy-chain variable region gene (IgV H ) mutation status, 1 genetic abnormalities identified by fluorescence in situ hybridization (FISH), 2 expression of ZAP-70 3 and CD38, 4 and chromosomal karyotyping. 5, 6 Of these, IgV H mutation status and FISH abnormalities have to our knowledge been studied most thoroughly and incorporated into clinical trials. These tests have evolved from providing purely prognostic information into becoming standard testing needed to personalize therapy. As a result, it has been recommended that they be performed in all patients newly diagnosed with CLL prior to therapy. 7 In contrast, lymph node biopsies generally are reserved for patients with CLL/SLL who do not present with peripheral blood lymphocytosis adequate for initial diagnosis, whereas bone marrow biopsies are no longer performed routinely but are reserved for particular clinical situations (eg, evaluating the cause of cytopenias). 8 The treatment of patients with CLL also has changed dramatically within a short time span because of the identification of new agents. Bendamustine was approved for frontline therapy for patients with CLL in 2008. 9 Since then, trials comparing bendamustine and rituximab (BR) versus fludarabine, cyclophosphamide, and rituximab (FCR) in patients of various ages were performed. A noninferiority study demonstrated more clinical benefit for patients aged <65 years who are treated with FCR, with no difference in clinical benefit noted between FCR and BR among older patients. 10 The Bruton tyrosine kinase inhibitor ibrutinib was approved for patients with recurrent CLL and for frontline therapy for patients with deletion of 17p (del17p) in 2014. 11 It was approved for frontline therapy in 2016. 12 The Surveillance, Epidemiology, and End Results (SEER) Patterns of Care (POC) study, sponsored by the National Cancer Institute, was conducted in a population of patients with CLL within participating SEER registries. We used this large population-based data set to compare testing and treatment patterns among patients with CLL who were diagnosed
Cancer January 1, 2019 in 2008 with those of patients diagnosed in 2014. We reviewed the National Comprehensive Cancer Network (NCCN) recommendations for testing and treatment for those years, 13 and compared differences in patterns by type of practice (teaching vs nonteaching hospitals).
MATERIALS AND METHODS
Data were obtained from the SEER POC studies. The SEER program collects cancer incidence and mortality data from 18 population-based registries that represent approximately 30% of the US population.
14 These registries primarily rely on hospital-based records for their cancer treatment information, and there are known data gaps in therapies (such as oral chemotherapy and hormone therapy) that are delivered in an outpatient setting. The POC studies were implemented to supplement routinely collected SEER information. 15 Each year, the SEER program selects certain cancer sites for which to abstract additional treatment information from a random sample of cases from 14 SEER registries. CLL cases diagnosed in 2008 and 2014 have been included in POC studies. CLL cases were defined by International Classification of Diseases for Oncology (ICD-O) histology code 9823. Additional case inclusion criteria included age ≥20 years at the time of diagnosis. Exclusion criteria included a previous history of cancer, synchronous diagnosis with another primary cancer, and cases diagnosed at autopsy.
For both years, the POC abstraction form included information regarding diagnostic procedures (bone marrow examination and lymph node biopsy), testing (FISH, chromosomal karyotype, and IgV H mutation testing), systemic therapies, and comorbid conditions. For both years, the list of systemic therapies included alemtuzumab, bendamustine, chlorambucil, cladribine, cyclophosphamide, fludarabine, flavopiridol, interferon, lenalidomide, obatoclax, pentostatin, prednisone, rituximab, and vincristine. For cases diagnosed in 2014, ibrutinib, idelalisib, obinutuzumab, and ofatumumab were added to the systemic therapies list. Information regarding the hospital that administered the most definitive therapy was collected based on the American Hospital Association-reported characteristics, which included bed size, residency training approval, and classification (profit vs nonprofit). The abstract form was completed by trained SEER abstractors from patient medical records up to 24 months after diagnosis. In addition, the treating physician was mailed a form to verify treatment and report any treatments that may have been administered in an outpatient setting.
Statistical Analysis
All analyses were completed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) and were weighted to account for the sampling design. Patient characteristics evaluated included sex, race/ethnicity, age in 10-year groups, Charlson Comorbidity Index, an areabased measure of socioeconomic status (SES) developed by Yost et al that uses US Census block group data, 16 and insurance status at the time of diagnosis. These characteristics were summarized by observed counts and weighted percentages. Percentages were weighted to accurately reflect the entire SEER population rather than absolute percentages of numbers observed among the sampled study cohort, which require adjusting because minority groups are overrepresented in the abstraction. The study abstractors recorded if each test was "performed," "not performed," or "unknown if performed." For both the "not performed" and "unknown if performed" categories, test results were not documented or available in the medical chart, and therefore these groups were combined in this analysis. Receipt of cytogenetics testing was summarized by observed count and weighted percentages and compared by diagnosis year using the Rao-Scott chisquare test. Weighted logistic regression was used to estimate the odd ratios (ORs) and 95% confidence intervals (95% CIs) for receipt of cytogenetic testing. Predictors evaluated included race/ethnicity and variables that were significantly different in univariate analysis (sex, age at diagnosis, insurance, and receipt of systemic treatment). ORs were estimated for all patients and stratified by age at diagnosis (age <65 years vs age ≥65 years) to assess differences between Medicare recipients with and without private insurance. The most common systemic treatment regimens by diagnosis year were summarized using observed count and weighted frequencies among those who received systemic therapy. This was stratified further by age at diagnosis (aged<70 years vs age ≥70 years), Charlson Comorbidity Index (0 vs ≥1), and whether the treating hospital had a residency program. Testing and treatment patterns were summarized by whether the treating hospital had a residency program (defined as a teaching hospital; those without residency programs were defined as nonteaching hospitals) and diagnosis year, and compared using the Rao-Scott chi-square test.
RESULTS

Baseline Characteristics
The current study included 1008 patients with CLL who were diagnosed in 2008 and 1367 patients who were
Cancer January 1, 2019 diagnosed in 2014. Demographics are depicted in Table 1 . Age, sex, race, SES, Charlson Comorbidity Index, and insurance status did not appear to differ between the 2 cohorts. Racial distributions reflect the SEER 14 population and historical trends, with non-Hispanic white individuals representing the majority of patients. 17 
Trends in CLL Testing
Testing patterns are shown in Table 2 . FISH for CLL was performed within 2 years of diagnosis for approximately 44% of all diagnosed patients in 2008, a figure that increased significantly to 51% of all patients in 2014 (P=.003). The distribution of FISH abnormalities did not differ by age (see Supporting Table 1 ). Among patients who were treated within 2 years of diagnosis, FISH testing occurred in the majority of but not all patients (53.4% of treated patients in 2008, which increased to 61.6% of treated patients in 2014). IgV H mutation analysis was performed infrequently during both time periods, but also increased significantly from 6% in 2008 to 11% in 2014 (P<.001).
Bone marrow biopsies decreased in frequency from 46% of all patients in 2008 to 39% of patients in 2014 (P=.002). However, lymph node biopsies were performed only rarely in 2008, but this increased substantially in 2014 (5% vs 27%; P<.001). Chromosomal karyotyping, which often is performed with bone marrow biopsies but can be performed with peripheral blood, demonstrated no difference in frequency of testing in 2008 compared with 2014 (35% in both years). Cancer January 1, 2019
In a separate analysis, we analyzed factors that determined receipt of FISH for CLL: age, sex, race, Charlson Comorbidity Index, SES, and insurance status ( 
Trends in Use of Frontline Treatments of CLL
The majority of patients with CLL remained untreated within the first 2 years of diagnosis (74% were untreated in 2008 and 71% were untreated in 2014). Of those patients who were treated within 2 years of diagnosis, we analyzed which frontline treatments were used in each time period (Table 4) . Among patients in 2008, FCR was the therapy used most often, followed by rituximab monotherapy, fludarabine and rituximab, and chlorambucil-based therapy. In 2014, BR was the most popular therapy, followed by rituximab monotherapy, FCR, and ibrutinib. In both time periods, chemoimmunotherapy was preferred over rituximab monotherapy in younger patients; however, BR was preferred over FCR in 2014. In both time periods, FCR was not commonly used for older patients or among patients with ≥1 comorbid condition.
There was a limited number of patients in whom to evaluate treatment patterns based on identified FISH abnormalities and IgV H mutation status. The number of patients separated by FISH abnormalities, IgV H mutation status, and being untreated or treated within 2 years from diagnosis is shown in Supporting Table 2 . Patients with higher risk CLL such as those with del17p, del11q, and unmutated IgV H status were treated more frequently in both time periods, with an increase in treatments among patients with del17p noted in 2014. This is presumably related to the known higher probability of an earlier onset of progressive disease in such patients. The majority of patients with del17p disease were treated with FCR in 2008 and with ibrutinib in 2014 (data not shown). Of the patients who received IgV H mutation status testing prior to treatment, a majority of these patients had unmutated IgV H status, with most receiving treatment with FCR in 2008 and BR in 2014 (data not shown).
Differences in Testing and Treatment Patterns by Practice Type
Differences in testing and treatment patterns between teaching and nonteaching hospitals are shown in Table 5 . FISH testing for CLL was more common in teaching hospitals compared with nonteaching hospitals in 2014, 18 which is a multisite, community-based registry consisting only of treated patients with CLL, because we are able to describe testing and treatment patterns within 2 years of diagnosis for all patients with CLL, including the majority of patients who initially are observed.
We reviewed the NCCN guidelines for the treatment of CLL from 2008 through 2010 and 2014 through the present. 13 FISH testing for CLL has been listed as "informative for prognostic determination" since 2009. However, since 2008, FISH testing has been incorporated into treatment algorithms for patients with progressive and symptomatic CLL, and treatment recommendations Abbreviations: BR, bendamustine and rituximab; CLL, chronic lymphocytic leukemia; CVP, cyclophosphamide, vincristine, and prednisone; FCR, fludarabine, cyclophosphamide, and rituximab; FR, fludarabine and rituximab; R, rituximab.
To protect patient confidentiality, only the 4 most common regimens are presented and any cell sizes <11 were suppressed. a Percentages were weighted by sampling fraction to reflect the Surveillance, Epidemiology, and End Results (SEER) 14 population from which the data were obtained.
Cancer January 1, 2019 are separated by those with or without del17p. Treatment recommendations also have been separated further by age (age <70 years or age ≥70 years) since 2008, and further separated by "frail, significant comorbidity" (not able to tolerate purine analogs) since 2009. With these distinct treatment algorithms put in place, it is not surprising that FISH is the most common test performed compared with other available prognostic testing. Use of FISH testing increased from 53% of treated patients in 2008 to 62% of treated patients in 2014. These frequencies are similar to those reported in the Connect CLL registry and suggest that further improvements can be made. 19 To the best of our knowledge, the reasons for a lack of testing remain unclear, although we identified disparities in the likelihood of testing by insurance type and age, with older patients and those without private insurance less likely to have testing performed over time. This is unfortunate because missing patients with del17p could worsen their clinical outcome through the use of less efficacious therapies, and treating older patients with del17p now is possible given available less toxic options such as ibrutinib. We also observed that FISH testing was more common in teaching hospitals compared with nonteaching hospitals, and therefore differences in practice may be contributing to the discrepancy. Because of the striking improvements in clinical outcomes noted among patients with del17p treated with ibrutinib and venetoclax, we expect that FISH testing for CLL will continue to increase in the future. 20, 21 In contrast, IgV H mutation analysis has remained prognostic and has not been incorporated into guideline treatment algorithms since 2009. Now that FCR also has been found to demonstrate a progression-free survival of >10 years in a sizeable percentage of patients with 24 also incorporate IgV H mutation analyses, as well as TP53 mutation testing, which have become more readily available recently.
Since 2009, guidelines state that flow cytometry of the blood is adequate for diagnosis, whereas bone marrow biopsies have been considered useful "under certain circumstances" since 2008. We observed that bone marrow biopsies were more commonly practiced in nonteaching hospitals compared with teaching hospitals in 2008, but had decreased in both hospital settings in 2014. However, the significant difference between the hospital settings again might reflect inconsistencies between practice types. In contrast, lymph node biopsies rarely were performed in 2008 and increased significantly in both hospital settings in 2014. To the best of our knowledge, it is unclear why the use of lymph node biopsies has increased. There were more patients with del11q in the 2014 cohort (see Supporting Table 2 ), and these patients often present with bulky lymphadenopathy. It also is possible that there were more cases of SLL in the latter cohort, and ICD-O coding does not separate CLL from SLL. In addition, it is conceivable that more biopsies were performed to rule out Richter transformation. Positron emission tomography scanning was recognized as a helpful tool with which to identify areas to biopsy that were concerning for transformation in 2014. 25 The overall differences in testing patterns between practice types have become more important given the current focus on low-value versus high-value testing. FISH testing would be considered a high-value test because it helps to determine appropriate therapy based on a patient's unique characteristics. Under insurance plans that follow value-based insurance design, 26, 27 a patient's out-of-pocket costs for high-value testing such as CLL FISH should be waived (ie, no cost). The Choosing Wisely campaign from the American Society of Hematology provides recommendations for avoiding low-value testing, and recommended avoiding baseline and serial computed tomography scans for patients with asymptomatic, early-stage CLL in 2014. 28 Routine bone marrow biopsies would be considered to be of low value because they infrequently change management and are invasive for patients. Well-designed, value-based clinical pathways might improve the proper use of selected pretreatment evaluations with predictive usefulness in both teaching and nonteaching hospital settings, and may distribute standard-of-care guidelines more consistently across practice types. 29 The differences in treatment regimens used during both time periods were consistent with the NCCN guideline algorithms for age and performance status/ comorbidities. It is interesting to note that, during both time periods, FCR was not commonly used for patients aged >70 years or those patients with ≥1 comorbidities. BR was used more frequently at the expense of FCR in 2014 among all patients. These trends regarding the top 4 frontline treatments received do not necessarily reflect the preferred treatments as listed in the NCCN guidelines by efficacy, but we believe they more accurately reflect preferences determined by a combination of age, comorbidities, and toxicity profiles. With the introduction of potent oral therapies such as ibrutinib and venetoclax, the options for patients who are frail and cannot tolerate chemotherapy as well as for those patients with high-risk disease have expanded. With these exciting new developments, we expect more changes in treatment patterns to occur in the future.
There are several limitations to the current study. Only a subset of patients with CLL were treated within 2 years of diagnosis, which limits the number of patients with which to analyze treatment patterns. The time of follow-up from diagnosis for each cohort was only 2 years, which limits our analysis regarding time to first treatment and treatment regimens used for patients with more indolent CLL. There was only a small subset of nonwhite patients in our data set, thereby limiting conclusions regarding any possible effects of racial disparities. Surprisingly, in our mostly elderly population of patients with CLL, only a minority of patients had ≥2 comorbidities according to the Charlson Comorbidity Index. The current study data set also lacked information regarding definitive staging (Rai or Binet). We also were unable to parse the different indications for rituximab monotherapy because rituximab may be used as treatment of autoimmune cytopenias rather than as systemic CLL therapy. We combined our "not performed" and "unknown" testing groups together, which potentially underestimates the frequency of testing. Despite this, we reported frequencies of FISH testing that were similar to those observed in other studies. We were unable to strictly delineate academic centers versus community practices with our data set and recognize that both academic and community practices have residency programs, but we still were able to observe differences between teaching and nonteaching hospital settings.
Cancer January 1, 2019 Testing and treatment patterns are changing dramatically in the modern era. The frequency of testing being incorporated into treatment decisions, particularly CLL FISH and IgV H mutation status, has increased from 2008 to 2014. Despite this increase in testing, there remains a significant number of patients who do not undergo FISH and/or IgVH mutation status testing prior to the initiation of therapy. Some disparities in testing were observed by age and insurance status. FCR was not found to be used commonly among patients who were elderly or had comorbidities. In more recent years, BR has been found to be used more frequently compared with FCR. There were differences in testing practices when teaching and nonteaching hospitals were compared, with FISH for CLL and IgV H mutation testing performed more frequently in teaching hospitals, and bone marrow biopsies performed more often in nonteaching hospitals. However, overall trends in the CLL therapies used remain similar in teaching and nonteaching hospitals. Given the rapid therapeutic developments in CLL, we anticipate dynamic changes in its future treatment patterns, and possibly therapies emerging free from standard chemotherapy. Fully evaluating the use of these therapies by practice type, and the access to these therapies among different patient populations, will be a vital focus of future studies.
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